Eurobio Scientific: agreement with Myriad Genetics

(CercleFinance.com) - Eurobio Scientific announces the signature of an agreement to acquire all rights to the EndoPredict second-generation breast cancer gene expression test from Myriad Genetics.


Following this acquisition, Eurobio Scientific will grant Myriad Genetics a license to manufacture, sell and distribute the EndoPredict breast cancer screening test for laboratory developed tests (LDT), mainly in the United States.

In addition, Myriad Genetics will grant Eurobio Scientific a license to manufacture, sell and distribute the Prolaris prostate cancer screening test kit. Completion of the transaction is scheduled for next July.

Copyright (c) 2024 CercleFinance.com. All rights reserved.